Ten Programs To Watch Out For At ASCO

The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.

Johnson & Johnson has the distinction of a late-breaking presentation on June 5 for the first quantitative data from its CASTOR study of Darzalex (daratumumab) in patients with relapsed/refractory multiple myeloma.

Darzalex received accelerated approval in November 2015 well ahead of schedule as a fourth-line treatment for multiple myeloma, but positive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

Sep 04 2025

• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

Sep 04 2025

• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Genmab/AbbVie’s Epkinly Could Get Competitive Edge With Outpatient Option

Sep 03 2025

• By Alaric DeArment

Phase II data showed it is feasible to give the CD20xCD3-targeting bispecific in the outpatient setting of DLBCL, while its current label calls for hospitalization.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

Aug 29 2025

• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

Sep 04 2025

• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.